ASCO Conference

ASCO Weighs in on CER

September 2010, Vol 1, No 4 - ASCO Conference

The American Society of Clinical Oncology (ASCO) stated that comparative effectiveness research (CER) should draw on approaches currently used for clinical trials, highlighting its stake in the matter by pointing out that CER is integral to oncology research. ASCO’s statement came in response to a request from the [ Read More ]

Bevacizumab Cost-Effectiveness “in Line” with Other Therapies

September 2010, Vol 1, No 4 - ASCO Conference

Chicago, IL—The cost-effectiveness of adding bevacizumab (Avastin) to first-line chemotherapy for the treatment of metastatic colorectal cancer is comparable to that of many other therapies for metastatic cancer. Although the acquisition cost of bevacizumab is high, it has improved the cost-effectiveness of systemic therapy (irinotecan [Camptosar]- or oxaliplatin-based [ Read More ]

Active Surveillance Cost-Effective for Low-Risk Prostate Cancer

September 2010, Vol 1, No 4 - ASCO Conference

Chicago, IL—Active surveillance is a cost-effective option for low-risk clinically localized prostate cancer. The number of quality-adjusted lifeyears (QALYs) was highest with active surveillance compared with radical prostatectomy, radiation therapy, brachytherapy, and proton beam therapy, according to data presented by Julia H. Hayes, MD, instructor in medicine [ Read More ]

Cost-Effectiveness in the New Comparative Effectiveness Landscape

September 2010, Vol 1, No 4 - ASCO Conference

Boston, MA—Cost-effectiveness can still add value in the comparative effectiveness landscape without it becoming woven into the politically caustic concept of healthcare allocation, according to 4 experts from academia, industry, and governmental agencies. The future of cost-effectiveness in the larger universe of comparative effectiveness research in a post–healthcare [ Read More ]